
10X Genomics (TXG) Stock Forecast & Price Target
10X Genomics (TXG) Analyst Ratings
Bulls say
10x Genomics Inc demonstrates a robust market position, evidenced by significant increases in Chromium reaction volumes, which indicate sustained demand despite potential pricing pressures. The company’s consumables revenue is projected to grow significantly, with estimates suggesting 5-19 times growth across various platforms by 2027, outpacing instrument revenue growth. This positive trend in consumables underscores the effectiveness of 10x Genomics's integrated solutions and reflects a favorable outlook for the company's financial performance moving forward.
Bears say
10x Genomics, Inc. has experienced significant challenges, including a contraction in 2024 characterized by double-digit pricing pressure and flat to modestly lower sales volumes, with growth not projected to recover until 2027. The company recently reported weaker than anticipated quarterly results, with an earnings per share (EPS) miss and a disappointing full-year revenue outlook, further contributing to investor concerns. Additionally, despite some expansion in its market segments since 2021, the growth has fallen short of analyst expectations, resulting in a stock price decline of over 90% from its peak.
This aggregate rating is based on analysts' research of 10X Genomics and is not a guaranteed prediction by Public.com or investment advice.
10X Genomics (TXG) Analyst Forecast & Price Prediction
Start investing in 10X Genomics (TXG)
Order type
Buy in
Order amount
Est. shares
0 shares